HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.

AbstractBACKGROUND:
Methylenetetrahydrofolate reductase is a pivotal enzyme in folate metabolism and 5-fluorouracil (5-FU) cytotoxicity. Two common single-nucleotide polymorphisms (SNPs), MTHFR 677C>T (rs1801133) and 1298A>C (rs1801131), reduce enzyme activity. Initially, these SNPs were claimed to predict clinical efficacy, but further studies have yielded contradictory results. We tested whether these two polymorphisms are determinants of clinical outcome in a large patient group with a long follow-up time.
PATIENTS AND METHODS:
We included 331 patients who had been treated with adjuvant 5-FU/leucovorin chemotherapy after intended curative resection between 1997 and 2003. Clinical data, including relapse rates, overall survival, and tumor stage, were collected. DNA was extracted from formalin-fixed tumor tissue and analyzed for the MTHFR 677C>T and 1298A>C SNPs with real-time PCR.
RESULTS:
The MTHFR 677C>T and 1298A>C polymorphisms were not associated with survival or relapse-free survival (P > 0.2). The 677 CC genotype was associated to toxicity (odds ratio = 1.83, P = 0.01).
CONCLUSIONS:
The MTHFR 677C>T and 1298A>C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C>T polymorphism may be associated with lower toxicity in 5-FU treatment. Implementation of SNP analysis for these polymorphisms for individualized treatment is premature.
AuthorsS Afzal, S A Jensen, B Vainer, U Vogel, J P Matsen, J B Sørensen, P K Andersen, H E Poulsen
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 20 Issue 10 Pg. 1660-6 (Oct 2009) ISSN: 1569-8041 [Electronic] England
PMID19465420 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • DNA, Neoplasm
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Fluorouracil
Topics
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Chemotherapy, Adjuvant
  • Colorectal Neoplasms (drug therapy, genetics, pathology)
  • DNA Mutational Analysis
  • DNA, Neoplasm (genetics, isolation & purification)
  • Denmark
  • Disease-Free Survival
  • Female
  • Fluorouracil (therapeutic use)
  • Humans
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
  • Middle Aged
  • Neoplasm Staging
  • Pharmacogenetics
  • Polymorphism, Genetic
  • Polymorphism, Single Nucleotide
  • Survival Rate
  • Treatment Outcome
  • White People

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: